Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
Go back to Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy| VERACYTE (NASDAQ: VCYT) | Delayed: 53.19 -0.44 (0.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $53.63 | 52 Week High | $8.45 | |||
| Open | $53.72 | 52 Week Low | $4.21 | |||
| Day High | $54.72 | P/E | N/A | |||
| Day Low | $52.36 | EPS | $-1.52 | |||
| Volume | 967,183 | |||||
